{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-051035","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.605918+00:00","generated_at":"2026-05-16T22:21:33.923214+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Skye Bioscience Q3: Nimacimab + semaglutide shows 29% greater weight loss vs semaglutide alone; net loss $12.8M","bullets":["Nimacimab plus semaglutide achieved 29% relative increase in weight loss vs semaglutide alone at 26 weeks; clean safety profile.","Combination reduced waist circumference by 3.2 cm (1.25 inches) vs semaglutide alone.","Rebound weight gain was 18.1% vs 49.8% for semaglutide alone over 12 weeks post-treatment.","Q3 2025 net loss of $12.8M; cash $35.3M; runway into 2027.","Extension study fully enrolled (43 patients); data expected Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-051035","json":"https://secwatch.observer/filing/0001628280-25-051035.json","markdown":"https://secwatch.observer/filing/0001628280-25-051035.md","text":"https://secwatch.observer/filing/0001628280-25-051035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000162828025051035/0001628280-25-051035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000162828025051035/skye-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:21:33.923214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}